Hjem
Eva Gerdtss bilde

Eva Gerdts

Professor, Medlem Det norske vitenskapsakademi
  • E-postEva.Gerdts@uib.no
  • Telefon+47 55 97 30 54+47 920 86 505
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen

Hjertesykdom hos kvinner er vårt overbyggende forskningsfokus. Hjertesykdom hos kvinner undersøkes i samarbeid med internasjonale partnere i Tyskland, Italia og USA. Hovedfokus er hjertesykdom som følge av høyt blodtrykk, aortaklaffestenose, fedme og autoimmune sykdommer, og hvordan disse faktorene belaster hjertet ulikt hos kvinner og menn. Vår forskning har bidratt til nye europeiske anbefalinger om behandling av høyt blodtrykk hos pasienter med aortaklaffstenose, og et internasjonalt fokus på hjertesykdom hos kvinner. Dette forsker vi på i norske befolkningsundersøkelser og i prosjekter med kliniske studier av personer med høyt blodtrykk, fedme, aortaklaffestenose, autoimmune sykdommer eller iskemisk hjerneslag. Et nytt Senter for forskning på hjertesykdom hos kvinner ble opprettet ved UiB juni 2020 finansiert av Hjertefondet ved UiB, Bergen Sanitetskvinner/Norske Kvinners Sanitetsforening og Grieg Foundation (https://www.uib.no/kvinnehjerte). Vår videre forskning vil tilknyttes Senterets nettverk.

Helseundersøkelsen i Hordaland - runde 3 (HUSK3) startet juni 2018 og vil pågå i 4 år. Hovedfokus er hva blodtrykk og andre helsefaktorer og endring i disse mens man er i 40-årene betyr for hjerte-kar helsen 20 år senere. Prosjektet er et samarbeid mellom 4 forskergrupper på UiB ledet av henholdsvis professor Grethe S. Tell, professor Ottar Nygård, professor Jutta Dierkes, undertegnede, BEVITAL akademisk laboratorium og Høgskolen på Vestlandet ved professor Marjolein Iversen. Se også: stipendiat Ester Kringeland, UiB

Ukontrollert høyt blodtrykk er et stort helseproblem i Norge. I samarbeid med de 4 øvrige universiteter forsker vi på dette i IDA studien. I samarbeid med overlege PhD Marianne Grytaas, endokrinologisk seksjon, medisinsk avdeling, Haukeland Universitetssykehus forsker vi på pasienter med primær aldosteronisme som underliggende årsak til høyt blodtrykk. Vårt hovedfokus er hvordan ukontrollert høyt blodtrykk påvirker hjertet, og om påvirkningen er forskjellig hos kvinner og menn eller utfra hva årsaken til det høye blodtrykket er. Se også: stipendiat Arleen Aune, UiB

Kvinner med autoimmune sykdommer har høy risiko for å få hjertesykdom tidlig. I samarbeid med revmatologisk avdeling, Haukeland Universitetssykehus studerer vi hjerteeffekten av moderne immunmodulerende behandling ved leddgikt. Se også: Postdoktor Helga Midtbø PhD, Haukeland Universitetssykehus

Subklinisk hjertekarsykdom hos unge slagpasienter undersøkes i NOR-SYS prosjektet i samarbeid med professor Ulrike Waje-Andreassen, nevrologisk avdeling, Haukeland Universitetssykehus. Hjerteultralydbilder fra den europeiske studien SECRETO på slagpasienter under 50 år sendes for analyse i våre kjernelaboratorium.

Kronikk Bergens Tidende 05.07.20

https://www.bt.no/btmeninger/debatt/i/6jxy13/kampen-om-kvinnehjertet

Intervju Undervisning i kvinnehelse i utdanning av helsearbeidere Dagsnytt 18, 16.04.20

https://tv.nrk.no/serie/dagsnytt-atten-tv/202004/NNFA56041620/avspiller

 

Intervju Ensomhet og kvinnehjertehelse Gro Holm NRK P1

https://radio.nrk.no/serie/holm/DMTO01024519

 

Hjertepraten, Litteraturhuset i Bergen 15.08.18

– Store kjønnsforskjeller ved hjerteinfarkt

Menn og kvinner har forskjellige risikofaktorer, symptomer og typer hjerteinfarkt, påpeker professor Eva Gerdts ved Klinisk institutt 2. Onsdag 15. august holder hun foredrag om temaet på Litteraturhuset i Bergen. Se innlegget på https://www.uib.no/med/119381/–-store-kjønnsforskjeller-ved-hjerteinfarkt eller på https://www.youtube.com/watch?v=t2lwuNonhOA.

https://forskning.no/nasjonal-kompetansetjeneste-for-kvinnehelse-kjonn-o...

 

Kvinnehjerter - en fagbok om vanlige hjertesykdommer

Løchen ML og Gerdts E. 2015, Oslo (Gyldendal Akademisk). ISBN: 978-8-205-46397-4. Boken kan bestilles ved å sende SMS med kodeord kvinnehjerter til 2030. Pris NOK 425

 

Underviser i profesjonsutdanning av leger ved UiB, semester MED5, MED11 og MED12. Undervisningen omfatter et praktisk kurs i hjerteultralydundersøkelse med håndholdt ultralydapparat, og forelesninger om høyt blodtrykk, hypertertensiv hjertesykdom og hjertesykdom hos kvinner. Organiserer fagdager om hjerteklaffsykdom hos eldre og symptomet tungpust.

PhD kurs NORHEART901 Cardiovascular imaging in research. Kursleder.

Underviser på nasjonale kurs i spesialistutdanning i indremedisin, nyresykdommer og hjertesykdommer

Vitenskapelig artikkel
  • 2013. The Norwegian stroke in the young study (NOR-SYS): rationale and design. BMC Neurology. 12 sider.
  • 2013. Prognostic Value of Energy Loss Index in Asymptomatic Aortic Stenosis. Circulation. 1149-1156.
  • 2012. Left Atrial Systolic Force and Outcome in Asymptomatic Mild to Moderate Aortic Stenosis. Echocardiography. 1038-1044.
  • 2012. Increased relative wall thickness is a marker of subclinical cardiac target-organ damage in African diabetic patients. Cardiovascular Journal of Africa. 435-441.
  • 2012. Global left ventricular load in asymptomatic aortic stenosis: covariates and prognostic implication (the SEAS trial). Cardiovascular Ultrasound.
  • 2012. Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: A LIFE study. American Journal of Hypertension. 1017-1023.
  • 2011. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart. 301-307.
  • 2010. Severe obstructive sleep apnea elicits concentric left ventricular geometry. Journal of Hypertension. 1074-1082.
  • 2010. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. Journal of Hypertension. 1534-1540.
  • 2010. Prognostic Significance of Left Ventricular Diastolic Dysfunction in Patients With Left Ventricular Hypertrophy and Systemic Hypertension (the LIFE Study). American Journal of Cardiology. 999-1005.
  • 2010. Myocardial deformation in aortic valve stenosis – relation to left ventricular geometry. Heart. 106-112.
  • 2010. Left atrial size and force in patients with systolic chronic heart failure: Comparison with healthy controls and different cardiac diseases. Experimental and clinical cardiology. e45-e51.
  • 2010. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. Journal of Hypertension. 1541-1546.
  • 2010. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). Journal of Hypertension. 377-383.
  • 2010. Impact of Baseline Severity of Aortic Valve Stenosis on Effect of Intensive Lipid Lowering Therapy (from the SEAS Study). American Journal of Cardiology. 1634-1639.
  • 2010. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in aortic stenosis [SEAS] substudy). American Journal of Cardiology. 1456-1460.
  • 2010. Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy). Blood Pressure. 140-144.
  • 2010. Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 1134-1140.
  • 2010. An unusual location of a papillary fibroelastoma. European Heart Journal-Cardiovascular Imaging.
  • 2009. Ultrasound in evaluation of post-interventional femoral vein obstruction: a case report. Cardiovascular Ultrasound. 14.
  • 2009. Quantitative contrast stress echocardiography in assessment of restenosis after percutaneous coronary intervention in stable coronary artery disease. European Heart Journal-Cardiovascular Imaging. 858-864.
  • 2009. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood Pressure. 180-186.
  • 2009. Myocardial Contrast Echocardiography in Assessment of Stable Coronary Artery Disease at Intermediate Dobutamine-Induced Stress Level. Echocardiography. 52-60.
  • 2009. Mitral E Wave Deceleration Time to Peak E Velocity Ratio and Cardiovascular Outcome in Hypertensive Patients During Antihypertensive Treatment (from the LIFE Echo-Substudy). American Journal of Cardiology. 1098-1104.
  • 2009. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovascular Imaging. 390-399.
  • 2009. Left ventricular long-axis function in treated haemochromatosis. The International Journal of Cardiac Imaging. 237-247.
  • 2009. Left ventricular diastolic function in patients with treated haemochromatosis. Scandinavian Cardiovascular Journal. 32-38.
  • 2009. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 306-312.
  • 2009. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. European Journal of Cardiovascular Prevention & Rehabilitation. 242-248.
  • 2009. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 634-640.
  • 2009. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 634-640.
  • 2008. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania. Cardiovascular Journal of Africa. 8-14.
  • 2008. Left ventricular structure in different types of chronic pressure overload. European Heart Journal, Supplement. E23-E30.
  • 2008. Left atrial volume in patients with asymptomatic aortic valve stenosis (the simvastatin and ezetimibe in aortic stenosis study). American Journal of Cardiology. 1030-1034.
  • 2008. Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension. 1472-1476.
  • 2008. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. New England Journal of Medicine. 1343-1356.
  • 2008. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). European Heart Journal-Cardiovascular Imaging. 809-815.
  • 2008. Gender differences in left ventricular structure and function during antihypertensive treatment - The Losartan intervention for Endpoint reduction in hypertension study. Hypertension. 1109-1114.
  • 2008. Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy in Response to Antihypertensive Therapy. Hypertension. 100-106.
  • 2008. Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy. Hypertension. 100-106.
  • 2008. Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS substudy). American Journal of Cardiology. 510-515.
  • 2008. Effects of Losartan in women with hypertension and left ventricular hypertrophy results from the Losartan Intervention For Endpoint Reduction in hypertension study. Hypertension. 1103-1108.
  • 2008. Clinical impact of ' in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension. 806-812.
  • 2008. Brain abscess caused by paradoxical embolization in Ebstein's anomaly. European Heart Journal-Cardiovascular Imaging. 105-106.
  • 2007. Reduced exercise capacity in genetic haemochromatosis. European Journal of Cardiovascular Prevention & Rehabilitation. 470-475.
  • 2007. Left atrial size and risk of major cardiovascular events during antihypertensive treatment - Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 311-316.
  • 2007. Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. American Journal of Hypertension. 771-776.
  • 2007. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. American Journal of Cardiology. 970-973.
  • 2006. Impact of hypertension on left ventricular hypertrophy regression and exercise capacity in patients operated for aortic valve stenosis. Scandinavian Cardiovascular Journal. 167-174.
  • 2006. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy - The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study. Circulation. 1588-1596.
  • 2006. Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Blood Pressure. 220-226.
  • 2005. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology. 705-711.
  • 2005. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology. 712-719.
  • 2004. Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 423-430.
  • 2004. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. Journal of Human Hypertension. 411-416.
  • 2004. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. American Heart Journal. 538-544.
  • 2004. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol - The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 1456-1462.
  • 2004. Prognostic significance of left ventricular mass change during treatment of hypertension. Journal of the American Medical Association (JAMA). 2350-2356.
  • 2004. Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 411-416.
  • 2004. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). Journal of Human Hypertension. 417-422.
  • 2004. Hypertensjon og hjertesykdom. Tidsskrift for Den norske legeforening. 802-805.
  • 2004. Essential hypertension in women. Blood Pressure. 272-278.
  • 2004. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). American Journal of Cardiology. 1076-1080.
  • 2004. Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians. Blood Pressure Monitoring. 167-172.
  • 2004. Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 397-402.
  • 2004. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. Journal of Human Hypertension. 453-459.
  • 2003. Pulse pressure/stroke index and left ventricular geometry and function:the Life Study. Journal of Hypertension. 781-787.
  • 2003. Left ventricular mass regression in the life study: effect of previous antihypertensive treatment. American Journal of Hypertension. 180-186.
  • 2003. Hjertesykdom ved genetisk hemokromatose. Hjerteforum. 16-20.
  • 2003. Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiograaphhic left ventricular hypertrophy The life study. Hypertension. 75-82.
  • 2002. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. American Heart Journal. 319-326.
  • 2002. Sex differences in left ventricular systolic function. Cardiology Review. 29-32.
  • 2002. Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). American Journal of Cardiology. 337-341.
  • 2002. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. Journal of Hypertension. 1445-1450.
  • 2002. Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Journal of Hypertension. 1223-1229.
  • 2002. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). American Journal of Cardiology. 399-402.
  • 2002. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 739-743.
  • 2002. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 227-232.
  • 2002. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 1071-1076.
  • 2002. Bruk av ekkokardiografi i hypertensjonsstudier. Hjerteforum. 77-83.
  • 2001. Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study. American Journal of Hypertension. 768-774.
  • 2001. Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. Kidney and Blood Pressure Research. 64-70.
  • 2001. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Journal of Hypertension. 127-134.
  • 2001. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. American Heart Journal. 784-791.
  • 2001. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). American Journal of Cardiology. 980-983.
  • 2001. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Pressure. 74-82.
  • 2000. Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. American Heart Journal. 624-630.
  • 2000. Left ventricular wall stresses and stress-mass products in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension. 1129-1138.
  • 2000. Left ventricular wall stresses and stress-mass products in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension. 1129-1138.
  • 2000. Left ventricular diastolic filling patterns in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. American Journal of Cardiology. 466-472.
  • 2000. Left ventricular diastolic filling patterns in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. American Journal of Cardiology. 466-472.
  • 2000. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE Study. Hypertension. 6-12.
  • 2000. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE Study. Hypertension. 6-12.
  • 2000. HOPE ett år senere. Hjerteforum. 31-35.
  • 2000. HOPE ett år senere. Hjerteforum. 31-35.
  • 1999. Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
  • 1999. Reproducibility of salt sensitivity testing using a dictary approach in essential hypertension. Journal of Human Hypertension. 375-384.
  • 1999. Early complications and long-term mortality after urgent or routine coronary angioplasty. Scandinavian Cardiovascular Journal. 33.
  • 1998. The Bergen Blood pressure Study: changes in cardiac structure and function in offspring of hypertensive families. European Heart Journal. 474-474.
  • 1998. Is salt sensitivity a temporary phenomenon? Journal of Hypertension. 150-150.
  • 1998. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE. Circulation. 1-205.
  • 1998. Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for months months. American Journal of Hypertension. 1178-1187.
  • 1998. Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using Captopril or Doxazosin for months. American Journal of Hypertension. 1178-1187.
  • 1998. Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using Captopril or Doxazosin for months. American Journal of Hypertension. 1178-1187.
  • 1998. Factors Influencing Left Ventricular Mass in Salt Sensitive and Salt Resistant Essential Hypertensive Patients. Blood Pressure. 223-230.
  • 1998. Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney International. 1455-1460.
  • 1997. Regression of left ventricular hypertrophy in type-1 diabetic patients using doxazosin as antihypertensive therapy @<abstract@>. Journal of Hypertension. 40.
  • 1997. Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • 1997. Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • 1997. Angiotensin converting enzyme inhibition and alpha<SUB>1</SUB>-receptor blockade as antihypertensive therapy in type-1 diabetic patients. American Journal of Hypertension. 121A.
  • 1996. Salt sensitivity in hypertensive type-1 diabetes mellitus. Blood Pressure. 78-85.
  • 1996. Salt sensitivity in hypertensive type-1 diabetes mellitus. Blood Pressure. 78-85.
  • 1996. Factors influencing left ventricular mass in hypertensive type-1 diabetic patients. American Journal of Hypertension. 65A.
  • 1994. Salt sensitive essential hyperdension evaluated by 24 hour ambulatory blood pressure. Blood Pressure. 375-380.
  • 1994. Salt sensitive essential hyperdension evaluated by 24 hour ambulatory blood pressure. Blood Pressure. 375-380.
  • 1994. Postoperative Doppler echocardiograpic evaluation in different sizes of Medtronic-Hall, Biocor and Carpentier-Edwards s.a.v. prosthetic-aortic valves. Scandinavian journal of thoracic and cardiovascular surgery. 25-29.
Vitenskapelig foredrag
  • 2003. Left atrial size and risk of major cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial).
  • 2002. The impact of concomitant diabtes on changes in left ventricular structure and function during antihypertensive treatment (the LIFE study).
  • 2002. Endocardial as well as midwll fractional shortening predict cardiovascular outcome in hypertension: The LIFE study.
  • 2001. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the LIFE study.
  • 2000. The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • 2000. The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • 2000. Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • 2000. Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • 2000. Parallel cardiac and renal damage in patients with left ventricular hypertrophy.
  • 2000. Parallel cardiac and renal damage in patients with left ventricular hypertrophy.
  • 2000. Inappropriate left ventricular mass is associated with high cardiovascular risk profile in hypertensive subjects.
  • 2000. Inappropriate left ventricular mass is associated with high cardiovascular risk profile in hypertensive subjects.
  • 2000. In hypertensive patients with left ventricular hypertrophy inappropriate left ventricular mass identifies high risk phenotypes.
  • 2000. In hypertensive patients with left ventricular hypertrophy inappropriate left ventricular mass identifies high risk phenotypes.
  • 2000. Change in diastolic left ventricular function after one year of antihypertensive treatment.
  • 2000. Change in diastolic left ventricular function after one year of antihypertensive treatment.
  • 2000. Antihypertensive therapy has greater impact on left ventrular hypertrophy reduction in women than men.
  • 2000. Antihypertensive therapy has greater impact on left ventrular hypertrophy reduction in women than men.
  • 1997. Hypertensive women with electrocardiographic left ventricular hypertrophy have Doppler echocardiographic indications of more impaired diastolic left ventricular function compared to men, at rest and during exercise.
  • 1996. Salt sensitivity in hypertensive type-1 diabetes mellitus.
  • 1996. Factors influencing left ventricular mass in hypertense type-1 diabetic patients.
  • 1995. Factors influencing the regression of left ventricular mass in men and women operated for aortic stenosis.
  • 1994. Plasma atial natriuretic peptide in salt sensitive hypertensive patients.
Sammendrag/abstract
  • 2014. Determinants of left ventricular systolic function after transcatheter aortic valve implantation. European Heart Journal-Cardiovascular Imaging.
  • 2013. Outcome in 1763 asymptomatic patients with mild or moderate calcific aortic stenosis followed prospectively with annual echocardiography. European Heart Journal. 334-334.
  • 2013. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment in patients with electrocardiographic left ventricular hypertrophy (LIFE). European Heart Journal. 597-597.
  • 2013. Hypertensive target organ damage predicts incident diabetes mellitus. European Heart Journal. 3419-3426.
  • 2013. Does rheumatoid arthritis predispose to abnormal left ventricular geometry independent of hypertension? European Heart Journal. 754-754.
  • 2013. Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry. Arthritis and Rheumatism. S182-S182.
  • 2013. Coronary artery plaque burden is a predictor of myocardial ischemia in non-ST elevation myocardial infarction in both genders. European Heart Journal. 74-75.
  • 2013. Arterial Stiffness Is Associated With Abnormal Left Ventricular Geometry In Patients With Rheumatoid Arthritis. Arthritis and Rheumatism. S174-S175.
  • 2012. Midwall left ventricular systolic function in asymptomatic aortic valve stenosis: is it prognostically important? The SEAS study. European Heart Journal. 97-98.
  • 2012. Covariates of global longitudinal strain and displacement in type 2 diabetes: a speckle tracking echocardiography study. European Heart Journal. 454-454.
  • 2011. Increased systolic strain rate early after transcatheter aortic valve implantation. European Heart Journal-Cardiovascular Imaging. ii37-ii37.
  • 2011. Impact of valvuloarterial impedance on cardiovascular outcome in patients with asymptomatic aortic stenosis. The SEAS study. Circulation.
  • 2011. Impact of aortic valve stenosis and hypertension on radial strain in multiple layers. European Heart Journal, Supplement. 1008-1009.
  • 2010. Risk factors for unexpected sudden death in patients with non-symptomatic aortic stenosis (the SEAS study). European Heart Journal. 886-887.
  • 2010. Left ventricular mass, an independent predictor of morbidity and mortality in aortic valve stenosis. European Heart Journal. 887-887.
  • 2010. Increased Relative Wall Thickness - A Frequent Marker of Subclinical Cardiac Target Organ Damage in African Diabetic Patients. Journal of Hypertension. E357-E357.
  • 2010. Hypoperfusion by contrast echocardiography predicts coronary artery disease severity in non-ST elevation myocardial infarction. European Heart Journal. 914-914.
  • 2010. Hypokalemi blunts left ventricular mass regression in hypertensive patients during losartan- or atenolol-based treatmend: The LIFE echo-substudy. Journal of Hypertension. E442-E443.
  • 2010. COMBINED USE OF ELECTROCARDIOGRAM AND ECHOCARDIOGRAM TO BETTER IDENTIFY HYPERTENSIVE PATIENTS AT HIGH RISK FOR HEART FAILURE. Journal of Hypertension. E214-E214.
  • 2009. Relation of degree of aortic valve calcification to left ventricular geometry and systolic function in asymptomatic aortic valve stenosis: A SEAS substudy. Journal of the American College of Cardiology. A410-A410.
  • 2009. Outcome of Asymptomatic Patients With Low Gradient "Severe" Aortic Valve Stenosis and Preserved Ejection Fraction - Results From the Prospective SEAS Study. Circulation. S371-S371.
  • 2009. Impact of severity of aortic valve stenosis on effect of intensive lipid-lowering therapy: The SEAS study. Journal of the American College of Cardiology. A415-A415.
  • 2009. ISOLATED SYSTOLIC HYPERTENSION IN PATIENTS WITH ASYMPTOMATIC AORTIC STENOSIS (A SEAS SUBSTUDY). Journal of Hypertension. S248-S248.
  • 2009. IMPACT OF STROKE VOLUME ON CARDIOVASCULAR RISK IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY (A LIFE SUBSTUDY). Journal of Hypertension. S319-S320.
  • 2009. Gender Differences in Outcome During Antihypertensive Therapy in Relation to Regression of Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study. Circulation. S1111-S1111.
  • 2009. Development of Systolic Dysfunction Not Related to Myocardial Infarction in Treated Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Echo Substudy. Circulation. S1164-S1165.
  • 2009. Compensatory or inappropriate left ventricular mass in asymptomatic aortic stenosis. Journal of the American College of Cardiology. A408-A409.
  • 2009. 2D Longitudinal Myocardial Strain: A More Sensitive Parameter of Left Ventricular Dysfunction in Aortic Valve Stenosis? Circulation. S372-S373.
  • 2008. The differential impact of static and pulsatile blood pressure components on regional myocardial deformation in patients with asymptomatic aortic valve stenosis. A SEAS substudy. Journal of Hypertension. S255-S256.
  • 2008. Impact of global afterload on left ventricular myocardial contractility in asymptomatic aortic stenosis: A SEAS substudy. Journal of the American College of Cardiology. A380-A380.
  • 2008. Impact of Pressure Recovery on Diagnosis of Severe Aortic Stenosis In Asymptomatic Patients. (A SEAS Substudy). Circulation. S931-S931.
  • 2008. Gender differences in left ventricular structure and function during antihypertensive treatment (the LIFE study). Journal of Hypertension. S275-S275.
  • 2007. Relationship of left ventricular Systolic function to persistence or development,of Electrocardiographic left ventricular hypertrophy in hypertensive patients: Implications for the development of new heart failure. Circulation. 473-473.
  • 2007. Pulse pressure - An independent predictor of left ventricular hyperthrophy in patients with asymptomatic aortic stenosis. A SEAS substudy. Circulation. 671-671.
  • 2007. Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during anti-hypertensive treatment: The LIFE echo-substudy. Circulation. 498-498.
  • 2007. Impact of left ventricular geometry on stress-corrected left ventricular systolic function in asymptomatic aortic valve stenosis. A SEAS substudy. Journal of the American College of Cardiology. 298A-299A.
  • 2007. Gender difference in the association of aortic valve sclerosis and cardiovascular events in hypertensive adults with left ventricular hypertrophy: The LIFE study. Circulation. 735-735.
  • 2007. Does metabolic syndrome influence reduction of ECG left ventricular hypertrophy? The LIFE study. Journal of Hypertension. S78-S78.
  • 2007. Association of aortic regurgitation with cardiovascular morbidity and mortality in hypertensive patients with left ventricle hypertrophy: The LIFE study. Circulation. 735-735.
  • 2006. Relationship of left atrial enlargement to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. Circulation. 366-366.
  • 2006. Prevalence and covariates of low left ventricular midwall shortening in patients with asymptomatic aortic valve stenosis. A SEAS substudy. Circulation. 656-657.
  • 2006. Impact of gender on left atrial and ventricular response to asymptornatic aortic valve stenosis. The SEAS study. Journal of the American College of Cardiology. 285A-286A.
  • 2005. Relationship of electrocardiographic strain pattern to left ventricular diastolic function in hypertensive patients: The LIFE study. Journal of the American College of Cardiology.
  • 2005. Influence of hypertension on angiographic findings in patients with angina pectoris. American Journal of Hypertension. 175A.
  • 2005. Impact of concomitant hypertension on left ventricular structure in patients with aortic valve stenosis. The SEAS study. European Heart Journal-Cardiovascular Imaging. S76.
  • 2005. Echocardiographic determinants of new-onset atrial fibrillation in patients with hypertension and electrocardiographic left ventricular hypertrophy: The LIFE study. Journal of the American College of Cardiology.
  • 2004. Tissue Doppler findings in patients with genetic hemochromatosis. Hjerteforum. 101.
  • 2004. Pulse pressure as cardiovascular risk marker during losartan or atenolol based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Trial). Journal of the American College of Cardiology. 448A.
  • 2004. Myocardial performance index independently predicts cardiovascular morbidity and mortality in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Journal of the American College of Cardiology. 227A.
  • 2004. Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Journal of the American College of Cardiology. 357A.
  • 2004. Ethnicity, left ventricular hypertrophy regressio and cardiovascular events in the LIFE echocardiography substudy. American Journal of Hypertension. A195.
  • 2004. Does losartan improve diastolic left ventricular function beetter than atenolol during more then four years of antihypertensive treatment? The LIFE Study. Circulation. 637.
  • 2004. Clinical and echocardiographic risk factors for congestive heart failure in controlled hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study). Circulation. 682-682.
  • 2004. Blood pressure and cardiovascular risk factors in hypertensive patients referred to a regional hospital in Ghana. American Journal of Hypertension. A196.
Vitenskapelig oversiktsartikkel/review
  • 2019. Sex differences in cardiometabolic disorders. 1657-1666.
  • 2018. Managing complications of hypertension in aortic valve stenosis patients. 897-907.
  • 2016. Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic. 915-926.
  • 2016. Atherosclerosis in Sjögren's syndrome: Evidence, possible mechanisms and knowledge gaps. 133-142.
  • 2013. Left ventricular geometry in obesity: Is it what we expect? 905-912.
  • 2010. Impact of ultrasound contrast agents in echocardiographic assessment of ischemic heart disease. 103-112.
  • 2004. Essential hypertension in women. 272-278.

Se fullstendig oversikt over publikasjoner i CRIStin.

FEMALE HEART project (kvinnehjerteprosjektet)

Prosjektet startet i 2012 som et samarbeid mellom vår forskergruppe og forskergrupper ved Norges arktiske universitet i Tromsø og Federico II Universitetet i Napoli, Italia. Prosjektet er translasjonelt og omfatter både dyreeksperimentelle og kliniske studier. Fokus er å forstå hvorfor høyt blodtrykk er mer skadelig for kvinnehjertet, og nye metoder for tidlig påvisning av slik hjerteskade. Prosjektet pågår fortsatt. En årlig Female Heart workshop arrangeres ved UiB for å spre ny kunnskap fra prosjektet. 

Helseundersøkelsen i Hordaland - 3. runde (HUSK3)

Startet 18.06.18. Fokus på hvordan høyt blodtrykk i 40 årene påvirker kvinner og menns helse når de er 20 år eldre. Oppfølging av 3000 personer. Første del av undersøkelsen foregår på Forskningsenhet for helseundersøkelser i Overlege Danielsens Hus. Andre del forgår på Hjerteavdelingens poliklinikk, 1. etasje i Sentralblokken på Haukeland Universitetsykehus. Prosjektet er et samarbeid mellom 5 forskergrupper ved UiB og Helse-Bergen.

Fedmeassosiert hjertekardysfunksjon (FATCOR)

Fokus på hvordan fedme påvirker hjertets- og pulsårenes funksjon hos kvinner og menn. Tverrsnittsundersøkelse av 620 friske personer med fedme. Prosjektet er et samarbeid mellom 3 forskergrupper ved UiB og Helse-Bergen.